Zai Lab (SEHK:9688, NASDAQ:ZLAB), a Qiming portfolio company that says that it focuses on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world, has been officially listed on The Stock Exchange of Hong Kong Limited's Main Board, it was reported on Sunday.
The issue price is HKD562 per share in the secondary listing and the stock opens at HKD613.5 per share, an increase of 9.16%, with a market cap of HKD52.724bn.
The firm has been listed on NASDAQ since 2017.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886